Novartis AG ADR (NVS) concluded trading on Thursday at a closing price of $97.86, with 3.11 million shares of worth about $304.51 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.47% during that period and on January 16, 2025 the price saw a loss of about -1.22%. Currently the company’s common shares owned by public are about 2.00B shares, out of which, 1.96B shares are available for trading.
Stock saw a price change of -2.35% in past 5 days and over the past one month there was a price change of -0.51%. Year-to-date (YTD), NVS shares are showing a performance of 0.57% which decreased to -9.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $92.35 but also hit the highest price of $120.92 during that period. The average intraday trading volume for Novartis AG ADR shares is 1.20 million. The stock is currently trading -0.37% below its 20-day simple moving average (SMA20), while that difference is down -3.54% for SMA50 and it goes to -8.12% lower than SMA200.
Novartis AG ADR (NYSE: NVS) currently have 2.00B outstanding shares and institutions hold larger chunk of about 6.76% of that.
The stock has a current market capitalization of $191.46B and its 3Y-monthly beta is at 0.58. PE ratio of stock for trailing 12 months is 11.41, while it has posted earnings per share of $8.57 in the same period. Its PEG reads 1.72 and has Quick Ratio of 0.90 while making debt-to-equity ratio of 0.74. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVS, volatility over the week remained 1.21% while standing at 1.14% over the month.
Analysts are in expectations that Novartis AG ADR (NVS) stock would likely to be making an EPS of 1.79 in the current quarter, while forecast for next quarter EPS is 1.83 and it is 8.34 for next year. For the current quarter EPS, analysts have given the company a lowest target 1.74 which is 1.84 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 1.53 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 17.24% while it is estimated to increase by 8.55% in next year. EPS is likely to grow at an annualized rate of 6.65% for next 5-years, compared to annual growth of 5.63% made by the stock over the past 5-years.
Coverage by BofA Securities stated Novartis AG ADR (NVS) stock as a Neutral in their note to investors on September 11, 2024, suggesting a price target of $130 for the stock. Stock get a Hold rating from Deutsche Bank on July 19, 2024.
